Market Access
Disease Awareness and Prelaunch Campaign for Flibanserin
Flibanserin is a medication approved for the treatment of pre-menopausal women with hypoactive sexual desire disorder.
Convention Panel
Journal Ad
Patient Website
Consensus Panel Branding and Materials
ARISTADA – Market Access Launch
ARISTADA, is a long-acting injectable atypical antipsychotic that is administered via intramuscular injection once every four to eight weeks for the treatment of schizophrenia. ARISTADAcombines proven efficacy with dosing flexibility to help meet the individual needs and treatment-management plans of patients living with schizophrenia.
Journal Ad
Treatment Authorization Request (TAR)
Payer Audience Monograph Series
Coding and Billing Summary
Patient Guide
Various Market Access Work
Procter & Gamble – Journal Ad Addressing OTC PPI Cost Saving Benefits.
UCP – Formulary Pull Through Materials
Boehringer Ingelheim – Patient Caregiver Brochures
NCQA – Annual Insights Brochure
AHS – Journal Ad
AHS – Journal Ad
AHS – Product Wholesaler Sellsheet
AHS – Disease Reprint Carrier
AHS – Outpatient Materials
Concept Work
PFIZER – Pain Management Pitch
OTSUKA – Rexulti Market Access Pitch